T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

Clinical trial NCT04160195 · TERMINATED

Trial details

NCT number: NCT04160195
Sponsor: National Cancer Institute (NCI)
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Lymphoma, B-Cell Lymphoma, Non-hodgkins Chronic Lymphocytic Leukemia B-Cell Chronic Lymphocytic Leukemia

Start date: 2019-12-20
Primary completion: 2021-06-11
Enrollment: 2

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.